Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
During the development of antimicrobial peptides (AMP) as potential therapeutics, antimicrobial susceptibility testing (AST) stands as an essential part of the process in identification and optimisation of candidate AMP. Standard methods for AST, developed almost 60 years ago for testing conventional antibiotics, are not necessarily fit for purpose when it comes to determining the susceptibility of microorganisms to AMP. Without careful consideration of the parameters comprising AST there is a risk of failing to identify novel antimicrobials at a time when antimicrobial resistance (AMR) is leading the planet toward a post-antibiotic era. More physiologically/clinically relevant AST will allow better determination of the preclinical activity of drug candidates and allow the identification of lead compounds. An important consideration is the efficacy of AMP in biological matrices replicating sites of infection, e.g., blood/plasma/serum, lung bronchiolar lavage fluid/sputum, urine, biofilms, etc., as this will likely be more predictive of clinical efficacy. Additionally, specific AST for different target microorganisms may help to better predict efficacy of AMP in specific infections. In this manuscript, we describe what we believe are the key considerations for AST of AMP and hope that this information can better guide the preclinical development of AMP toward becoming a new generation of urgently needed antimicrobials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449 · cited 2×
“Most AST, and its interpretation, is conducted using internationally recognised standards developed by bodies including the International Organization for Standardization (ISO), Clinical and Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST), The United State…”
BackgroundMethodAntimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457 · cited 1×
“…properties, whereas HDP are essential innate host defence effector molecules and are amongst the “first responders” in all eukaryotic and some prokaryotic organisms to infectious challenge or an inflammation (Zasloff, 2002; Hassan et al., 2012; Mansour et al., 2014; Kang et al., 2017).”
BackgroundWiegand, I., Hilpert, K., & Hancock, R. E. W. (2008) · Nature Protocols · doi:10.1038/nprot.2007.521 · Cited by 6,156
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Brogden, K. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1098 · Cited by 5,829 · cited 1×
“…properties, and are able to target microorganisms through diverse mechanisms of action, although the most common mechanism of action is membrane perturbation/lysis (Brogden, 2005; Hancock and Sahl, 2006; Le et al., 2017; Pyne et al., 2017; Kumar et al., 2018; Aisenbrey et al., 2019).”
BackgroundAntibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
HMDB 4.0: the human metabolome database for 2018
Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., Sajed, T., Johnson, D., Li, C., Karu, N., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1089 · Cited by 3,438
O'Toole, G. A., & Kolter, R. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00797.x · Cited by 2,537
Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
Cited by
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Self-citationConfidence-based prediction of antibiotic resistance at the patient level
Inda-Díaz, J. S., Johnning, A., Hessel, M., Sjöberg, A., Lokrantz, A., Helldal, L., Jirstrand, M., Svensson, L., & Kristiansson, E. (2026) · mBio · doi:10.1128/mbio.03431-25 · Cited by 7
Metadata
- Authors
- Mercer, D. K., Torres, M. D. T., Duay, S. S., Lovie, E., Simpson, L., von Köckritz-Blickwede, M., de la Fuente-Nunez, C., O'Neil, D. A., & Angeles-Boza, A. M.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-07
- Volume
- 10
- Pages
- 326-326
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W3036187415
- Cited by
- 132
- References
- 40
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy. https://app.cochat.ai/papers/10.3389/fcimb.2020.00326
- The paper
- Mercer, D. K., Torres, M. D. T., Duay, S. S., Lovie, E., Simpson, L., von Köckritz-Blickwede, M., de la Fuente-Nunez, C., O'Neil, D. A., & Angeles-Boza, A. M. (2020). Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2020.00326
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.